Initial Public Offerings

Endocyte again changes terms of public offering

February 4, 2011
 IBJ Staff and Bloomberg News
The West Lafayette-based biopharmaceutical company now is planning to offer at least 12.5 million shares, or 17 percent more than previously announced, but at a lower price of $6 each.

Endocyte prices IPO stock

January 14, 2011
J.K. Wall
The West Lafayette-based drug development firm intends to sell 6.15 million shares for $13 to $15 apiece. That would fetch $80 million to $92 million.

Vera Bradley shares off to impressive start

October 21, 2010
Stock in the Fort Wayne-based company began trading Thursday morning at $16 but climbed as high as $23.90.

Vera Bradley set to go public

October 20, 2010
Scott Olson
The Fort Wayne-based company is scheduled to begin trading as a public company Wednesday morning. The estimated offering price is $14 to $16 each, although a Morningstar analyst predicts the IPO could bring as much as $18 a share.

Endocyte's $86M IPO plan a boon for Indiana, investors

August 28, 2010
Greg Andrews
Venture capitalists in Indiana and nationally have thrown money at the company with abandon. Local investors include CID Capital, Clarian Health Ventures and the Indiana Future Fund.

Cancer drug developer Endocyte files for IPO

August 18, 2010
Scott Olson
The company, headquartered at Purdue Research Park, said the number of shares to be offered and their price range have yet to be determined.

Vera Bradley files for $175M IPO

July 1, 2010
 IBJ Staff
The 28-year-old company reported profit in its latest fiscal year of $43.2 million on $288.9 million in sales.

EDITORIAL: Lots of promising local firms in IPO pipeline

June 5, 2010
There’s a reason we’re thrilled to see the Indianapolis area is building a healthy pipeline of firms primed to go public: It bodes well for our economy.

Private companies struggle to raise funds once reaching critical massRestricted Content

May 29, 2010
Peter Schnitzler
Several Indiana companies are in a position, or soon will be, to launch an initial public offering. But don't expect a wave of new Indiana public companies. In the recession, with both revenue and profits down, companies may choose to wait until they have better numbers to report.

Rapid growth makes Aprimo candidate for another try at IPO

March 6, 2010
Chris O'Malley
Robust growth at marketing software maker Aprimo is fueling speculation it is about to make another run at going public, and co-founder Bill Godfrey said he won't rule out the possibility of an IPO.

UPDATE: KAR Auction IPO raises less than hoped

December 10, 2009
Associated Press
The Carmel-based auctioneer had expected to raise $340.9 million through its IPO, but the company said it would sell 25 million common shares at $12 each for total proceeds of $300 million.

Australian owner abandons efforts to sell Chase TowerRestricted Content

September 19, 2009
Greg Andrews
Macquarie Office Trust of Sydney has quietly pulled the 48-story Chase Tower off the market, along with a property in Boston and a property in Denver that failed to draw juicy enough offers.

Omnicity seeks financial turnaround, has 28 acquisitions in mind

April 13, 2009
Chris O'Malley
Dick Beltzhoover, a private investor in Omnicity Corp., a Carmel-based wireless broadband provider, has quietly taken the company public and has lofty plans to expand nationwide.
Page  << 1 2 3 pager
Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ
  1. By Mr. Lee's own admission, he basically ran pro-bono ads on the billboard. Paying advertisers didn't want ads on a controversial, ugly billboard that turned off customers. At least one of Mr. Lee's free advertisers dropped out early because they found that Mr. Lee's advertising was having negative impact. So Mr. Lee is disingenous to say the city now owes him for lost revenue. Mr. Lee quickly realized his monstrosity had a dim future and is trying to get the city to bail him out. And that's why the billboard came down so quickly.

  2. Merchants Square is back. The small strip center to the south of 116th is 100% leased, McAlister’s is doing well in the outlot building. The former O’Charleys is leased but is going through permitting with the State and the town of Carmel. Mac Grill is closing all of their Indy locations (not just Merchants) and this will allow for a new restaurant concept to backfill both of their locations. As for the north side of 116th a new dinner movie theater and brewery is under construction to fill most of the vacancy left by Hobby Lobby and Old Navy.

  3. Yes it does have an ethics commission which enforce the law which prohibits 12 specific items. google it

  4. Thanks for reading and replying. If you want to see the differentiation for research, speaking and consulting, check out the spreadsheet I linked to at the bottom of the post; it is broken out exactly that way. I can only include so much detail in a blog post before it becomes something other than a blog post.

  5. 1. There is no allegation of corruption, Marty, to imply otherwise if false. 2. Is the "State Rule" a law? I suspect not. 3. Is Mr. Woodruff obligated via an employment agreement (contractual obligation) to not work with the engineering firm? 4. In many states a right to earn a living will trump non-competes and other contractual obligations, does Mr. Woodruff's personal right to earn a living trump any contractual obligations that might or might not be out there. 5. Lawyers in state government routinely go work for law firms they were formally working with in their regulatory actions. You can see a steady stream to firms like B&D from state government. It would be interesting for IBJ to do a review of current lawyers and find out how their past decisions affected the law firms clients. Since there is a buffer between regulated company and the regulator working for a law firm technically is not in violation of ethics but you have to wonder if decisions were made in favor of certain firms and quid pro quo jobs resulted. Start with the DOI in this review. Very interesting.